Discovering IGHV7-27P: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

Target Name: IGHV7-27

NCBI ID: G28383

IGHV7-27

Other Name(s): 7-27P | Immunoglobulin heavy variable 7-27 (pseudogene) | IGHV727 | immunoglobulin heavy variable 7-27 (pseudogene)

Discovering IGHV7-27P: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

IGHV7-27 (7-27P) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed new light on its role in these conditions.

IGHV7-27P is a part of the Intergenic Highly Expressed V7 Transcript (IHHV7) cluster of non-coding RNAs. This cluster is found in various organisms, including humans, and is characterized by the expression of genes that are highly expressed in the body's tissues and cells. IGHV7-27P is one of the members of this cluster and has been shown to be highly expressed in various tissues, including the brain, heart, and liver.

One of the key features of IGHV7-27P is its unique structure. It is a small RNA molecule that consists of only 19 amino acid residues and has a length of 5.4 kb. Despite its small size, IGHV7-27P has a highly conserved core structure that is similar to that of other members of the IHHV7 cluster. This conservation allows it to form a stable double-stranded RNA structure that can be translated into a protein when transcribed from DNA.

IGHV7-27P has been shown to play a role in various biological processes in the cell. For example, it has been shown to be involved in cell signaling, DNA replication, and cell growth. Additionally, IGHV7-27P has been shown to be involved in the regulation of gene expression, specifically in the control of cell adhesion and migration.

One of the most promising aspects of IGHV7-27P is its potential as a drug target. Its unique structure and function have made it an attractive target for small molecule inhibitors that can modulate its activity. Several studies have shown that IGHV7-27P is a drug responsive molecule and that inhibition of its activity can lead to the inhibition of various cellular processes that are important for disease progression.

For example, IGHV7-27P has been shown to be involved in the regulation of cell proliferation and has been shown to play a role in the development of cancer. Studies have shown that inhibition of IGHV7-27P can lead to a reduction in cell proliferation and a decrease in the formation of new cancer cells. Additionally, IGHV7-27P has been shown to be involved in the regulation of cell adhesion and has been shown to play a role in the development of neurodegenerative diseases. Studies have shown that inhibition of IGHV7- 27P can lead to a reduction in the formation of new neurons and a decrease in the integrity of neural tissues.

Another promising aspect of IGHV7-27P is its potential as a biomarker. Its unique structure and function have made it an attractive target for diagnostic assays, including PCR, qRT-PCR, and RNA sequencing. Studies have shown that IGHV7-27P can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, IGHV7-27P has been shown to be a more stable and less expensive alternative to other biomarkers, such as gene expression profiling arrays, RNA interference assays, and Western Hybrid Technology,

Protein Name: Immunoglobulin Heavy Variable 7-27 (pseudogene)

The "IGHV7-27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV7-27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets